CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+66.99%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$485M
AUM Growth
+$485M
(+30%)
Cap. Flow
+$108M
Cap. Flow
% of AUM
22.25%
Top 10 Holdings %
Top 10 Hldgs %
56.78%
Holding
69
New
16
Increased
8
Reduced
9
Closed
5
Top Buys
| 1 |
Puma Biotechnology
PBYI
|
$71.6M |
| 2 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
$16.8M |
| 3 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
$13.8M |
| 4 |
Neurocrine Biosciences
NBIX
|
$8.62M |
| 5 |
Tempest Therapeutics
TPST
|
$8.57M |
Top Sells
| 1 |
QCOR
QUESTCOR PHARMA INC
QCOR
|
$18.5M |
| 2 |
CELG
Celgene Corp
CELG
|
$17.2M |
| 3 |
Omeros
OMER
|
$7.31M |
| 4 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$7.2M |
| 5 |
Merck
MRK
|
$5.79M |
Sector Composition
| 1 | Healthcare | 79.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Puma Biotechnology
PBYI
$254M
| $121M | 24.9% | 507,500 +300,000 | +145% | +$71.6M |
|
|
RCPT
2
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
| $46.5M | 9.56% | 748,700 +269,900 | +56% | +$16.8M |
|
3
Jazz Pharmaceuticals
JAZZ
$7.75B
| $16.1M | 3.3% | 100,000 | – | – |
|
|
DYAX
4
DELISTED
DYAX CORPORATION
DYAX
| $15.2M | 3.12% | 1,500,000 -300,000 | -17% | -$3.04M |
|
|
KERX
5
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $13.8M | 2.83% | +1,000,000 | New | +$13.8M |
|
6
Karyopharm Therapeutics
KPTI
$61.7M
| $13.5M | 2.77% | 385,000 | – | – |
|
|
7
Neurocrine Biosciences
NBIX
$13.8B
| $13.3M | 2.74% | 850,000 +550,000 | +183% | +$8.62M |
|
8
Arrowhead Research
ARWR
$3.05B
| $13.3M | 2.73% | 900,000 | – | – |
|
|
XLRN
9
DELISTED
Acceleron Pharma Inc.
XLRN
| $12.1M | 2.49% | 400,000 +200,000 | +100% | +$6.05M |
|
10
BioCryst Pharmaceuticals
BCRX
$1.74B
| $10.8M | 2.21% | 1,100,000 -68,000 | -6% | -$665K |
|
11
Akebia Therapeutics
AKBA
$833M
| $8.85M | 1.82% | 400,000 | – | – |
|
|
12
Tempest Therapeutics
TPST
$44M
| $8.57M | 1.76% | +516,200 | New | +$8.57M |
|
|
TSRO
13
DELISTED
TESARO, Inc.
TSRO
| $8.08M | 1.66% | 300,000 | – | – |
|
14
DexCom
DXCM
$29.5B
| $8M | 1.65% | 200,000 | – | – |
|
15
Bristol-Myers Squibb
BMY
$96B
| $7.68M | 1.58% | +150,000 | New | +$7.68M |
|
|
16
Omeros
OMER
$283M
| $6.97M | 1.43% | 547,900 -575,100 | -51% | -$7.31M |
|
|
CMRX
17
DELISTED
Chimerix, Inc.
CMRX
| $6.91M | 1.42% | 250,000 -50,000 | -17% | -$1.38M |
|
|
GEVA
18
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
| $6.88M | 1.41% | +100,000 | New | +$6.88M |
|
19
Ultragenyx Pharmaceutical
RARE
$2.89B
| $6.79M | 1.4% | 120,000 | – | – |
|
20
Novavax
NVAX
$1.21B
| $6.26M | 1.29% | 1,500,000 | – | – |
|
21
Agios Pharmaceuticals
AGIO
$2.19B
| $6.14M | 1.26% | +100,000 | New | +$6.14M |
|
22
Heron Therapeutics
HRTX
$207M
| $5.83M | 1.2% | 700,000 | – | – |
|
23
Ardelyx
ARDX
$1.53B
| $5.52M | 1.14% | +388,700 | New | +$5.52M |
|
24
PTC Therapeutics
PTCT
$3.92B
| $5.5M | 1.13% | 125,000 -25,000 | -17% | -$1.1M |
|
25
Talphera
TLPH
$11.1M
| $5.49M | 1.13% | 1,000,000 +300,000 | +43% | +$1.65M |
|